Find Clinical Trial
A study of PRS-344/S095012 (PD-L1x4-1BB bispecific antibody) in patients with solid tumors
← Back
| Study Phase |
Phase 1-2 |
| Therapeutic Area |
Cancers |
| Indication | Solid tumors |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S) and Pieris Pharmaceuticals |
| Active substance/ Medical device |
Solid tumors |
| Active Substance Code | PRS-344/S095012 |
| Protocol Code | CL1-95012-001 |
| EudraCT Code | 2019-003456-36 |
| NCT Code | NCT05159388 |
Documents and links
| Results are not yet available. |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
